Supplemental Figure 6 from Combination Drug Scheduling Defines a 'Window of Opportunity' for Chemopotentiation of Gemcitabine by an Orally Bioavailable, Selective ChK1 Inhibitor, GNE-900

Authors :: Shiva Malek
Peter K. Jackson
Jason Halladay
Karen Williams
Lewis Gazzard
Gary Cain
Sharon Yee
Diana Jakubiak
Kenton Wong
Judi Ramiscal
Kaska Kowanetz
Jonathan Choi
Yang Xiao
Stephen Schmidt
Marie Evangelista
Tom O'Brien
Michael Flagella
Ivana Yen
Jennifer Epler
Elizabeth Blackwood
Publication Year :: 2023
Publisher :: American Association for Cancer Research (AACR), 2023.
Abstract: GNE-900 potentiates the cytotoxicity of gemcitabine in HCT-116 isogenic variants, irrespective of NHEJ competence.

Full Text Access

Tools